Investigational drug · Phase 2
BNT166a
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "BNT166a"
First trial start
2023
Sep 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BNT166a", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mpox (Monkeypox)
- Smallpox
- Orthopoxvirus Infection
- Monkeypox
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "BNT166a" as an intervention, largest first.
- A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in AfricaPivotal-lookingRecruiting
BioNTech SEIndustry
NCT07379580 · 310 participants (planned) · Start Feb 20, 2026 · Primary completion Jun 2027
Drug: BNT166a · For: Mpox (Monkeypox); Smallpox; Orthopoxvirus Infection
Sites: Kinshasa, Democratic Republic of the Congo; Cape Town, South Africa; Johannesburg, South Africa · 6 sites in all
BioNTech SEIndustry
NCT05988203 · 96 participants · Start Sep 21, 2023 · Primary completion Aug 25, 2025
Drug: BNT166a · For: Monkeypox
Sites: San Diego, California; Kansas City, Missouri; Knoxville, Tennessee · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial.
Bähner F, Faust SN, Davies LRL, et al. · Lancet Infect Dis 2026
- A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease.
Zuiani A, Dulberger CL, De Silva NS, et al. · Cell 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.